enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. 13 Best Hormonal Acne Treatments for Reducing ... - AOL

   www.aol.com/entertainment/13-best-hormonal-acne...

   It turns out that this resurgence of inflammatory acne (known as hormonal acne) is especially common in women between the ages of 20 and 50. 7 Celebrity-Approved Products on Amazon to Help Combat Acne

3. The 14 Best Acne Spot Treatments, According To Editors And ...

   www.aol.com/lifestyle/14-best-acne-spot...

   February 20, 2024 at 3:44 PM ... Keep scrolling to find the 14 best acne spot treatments recommended by Women's Health editors and skin ... making it suitable to use all over the face or as a spot ...

4. Everything You Need to Know About Acne, from Causes to Treatment

   www.aol.com/everything-know-acne-causes...

   Almost 5 percent of women ages 20 through 29. 35 percent of women ages 30 through 39 ... and can cause acne in both men and women ... doctor before starting any acne treatment, even if it’s over ...

5. Clascoterone - Wikipedia

   en.wikipedia.org/wiki/Clascoterone

   Clascoterone is indicated for the topical treatment of acne vulgaris in people aged twelve years of age and older. [5] [13] Two large phase III randomized controlled trials evaluated the effectiveness of clascoterone for the treatment of acne over a period of 12 weeks. [5] [13] [14] Clascoterone decreased acne symptoms by about 8 to 18% more ...

6. Flutamide - Wikipedia

   en.wikipedia.org/wiki/Flutamide

   Flutamide has been researched and used extensively in the treatment of androgen-dependent skin and hair conditions in women including acne, seborrhea, hirsutism, and scalp hair loss, as well as in hyperandrogenism (e.g., in polycystic ovary syndrome or congenital adrenal hyperplasia), and is effective in improving the symptoms of these conditions.

7. Medical uses of bicalutamide - Wikipedia

   en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

   Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...